BREAKING

Key highlights from Fastenal’s (FAST) Q1 2026 earnings results 3 hours ago SiTime Corporation Jumps 5.2% in Broad Rally 3 days ago Guidewire Software Drops 5.9% Amid Sector-Wide Selling 3 days ago Korn Ferry Drops 5.5% in Broad Selloff 3 days ago Commvault Systems (CVLT) Jumps 9.8% to $88.47 3 days ago Nexstar Media Group Stock Jumps 5% Amid Sector-Wide Rally 3 days ago TransMedics Group Shares Jump 5.0% 3 days ago Rambus Inc. Jumps 6.3% 3 days ago Clear Secure, Inc. Drops 6.1% in Broad Selloff 3 days ago DigitalOcean Holdings, Inc. Drops 7.2% in Broad Selloff 4 days ago Key highlights from Fastenal’s (FAST) Q1 2026 earnings results 3 hours ago SiTime Corporation Jumps 5.2% in Broad Rally 3 days ago Guidewire Software Drops 5.9% Amid Sector-Wide Selling 3 days ago Korn Ferry Drops 5.5% in Broad Selloff 3 days ago Commvault Systems (CVLT) Jumps 9.8% to $88.47 3 days ago Nexstar Media Group Stock Jumps 5% Amid Sector-Wide Rally 3 days ago TransMedics Group Shares Jump 5.0% 3 days ago Rambus Inc. Jumps 6.3% 3 days ago Clear Secure, Inc. Drops 6.1% in Broad Selloff 3 days ago DigitalOcean Holdings, Inc. Drops 7.2% in Broad Selloff 4 days ago

ADVERTISEMENT

RE

REGN

All REGN Content

43 articles, transcripts, and reports

Regeneron Pharmaceuticals Inc (REGN) Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release

April 13, 20261 min read

Regeneron Pharmaceuticals Inc (REGN) Sec Form 8K

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Sec Form 8K

April 9, 20261 min read

Regeneron Pharmaceuticals Inc (REGN) Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release

April 2, 20261 min read

Regeneron Pharmaceuticals Inc (REGN) TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release

April 2, 20261 min read

ADVERTISEMENT

Regeneron Pharmaceuticals Inc (REGN) EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release

April 2, 20261 min read

Regeneron Pharmaceuticals Inc (REGN) Q1 2026 Earnings Call

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q1 2026 Earnings Conference

March 25, 20261 min read

Regeneron Pharmaceuticals Inc (REGN) Q1 2026 Earnings Announcement

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q1 2026 Earnings Announcement

March 25, 20261 min read

Regeneron Pharmaceuticals Inc (REGN) Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release

March 24, 20261 min read

ADVERTISEMENT

Regeneron Pharmaceuticals Inc (REGN) Q1 2025 Earnings Call

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q1 2025 Earnings Conference

March 18, 20261 min read

Regeneron Pharmaceuticals Inc (REGN) Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release

March 10, 20261 min read